Nautilus Biotechnology, Inc.

Equities

NAUT

US63909J1088

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-04-22 pm EDT 5-day change 1st Jan Change
2.42 USD -1.63% Intraday chart for Nautilus Biotechnology, Inc. -1.63% -19.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Nautilus Biotechnology, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Nautilus Biotechnology, Inc., Q3 2023 Earnings Call, Oct 31, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Nautilus Biotechnology, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:50 AM
Transcript : Nautilus Biotechnology, Inc., Q2 2023 Earnings Call, Aug 02, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Nautilus Biotechnology, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 04:40 PM
Transcript : Nautilus Biotechnology, Inc., Q1 2023 Earnings Call, May 02, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Nautilus Biotechnology, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Nautilus Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Nautilus Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nautilus Biotechnology Expands to San Diego CI
Nautilus Biotechnology, Translational Genomics Research Institute Team Up to Advance Study in Childhood Cancer MT
Nautilus Biotechnology, Inc. Partners with the Translational Genomics Research Institute to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma CI
Transcript : Nautilus Biotechnology, Inc., Q3 2022 Earnings Call, Nov 01, 2022
Nautilus Biotechnology, Inc. Appoints Karen Akinsanya to Nominating Committee CI
Nautilus Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Global markets live: Ford, Biogen, Exxon, Generac Holdings, Nautilus... Our Logo
Sterling's fall and recession fears sent Wall Street in bear territory Our Logo
MarketScreener's World Press Review : September 27, 2022 Our Logo
Transcript : Nautilus Biotechnology, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 11:05 AM
Goldman Sachs Halves Price Target on Nautilus Biotechnology to $2 From $4 Amid Product Launch Delay; Neutral Rating Kept MT
Chart Nautilus Biotechnology, Inc.
More charts
Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Calendar
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
2.42 USD
Average target price
4.25 USD
Spread / Average Target
+75.62%
Consensus
  1. Stock Market
  2. Equities
  3. NAUT Stock
  4. News Nautilus Biotechnology, Inc.
  5. Nautilus Biotechnology Shares Rise After Company's Q2 Loss Narrows